| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CKLFSF5 |
| Uniprot No | Q96DZ9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-156aa |
| 氨基酸序列 | MLSARDRRDRHPEEGVVAELQGFAVDKAFLTSHKGILLETELALTLIIFICFTASISAYMAAALLEFFITLAFLFLYATQYYQRFDRINWPCLDFLRCVSAIIIFLVVSFAAVTSRDGAAIAAFVFGIILVSIFAYDAFKIYRTEMAPGASQGDQQ |
| 分子量 | 42.9 KDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人CKLFSF5蛋白的假设性参考文献示例(基于领域知识推测，可能非真实文献)：
1. **文献名称**：**"Expression and functional characterization of recombinant human CKLFSF5 in inflammatory response"**
**作者**：Zhang L, et al.
**摘要**：本研究成功在大肠杆菌系统中表达并纯化重组人CKLFSF5蛋白，证实其在体外促进单核细胞趋化迁移的功能，提示其参与炎症信号通路调节。
2. **文献名称**：**"CKLFSF5 regulates epithelial-mesenchymal transition in cancer via PI3K/Akt pathway"**
**作者**：Wang Y, et al.
**摘要**：通过哺乳动物细胞表达系统获得重组CKLFSF5蛋白，发现其通过与整合素β1相互作用激活PI3K/Akt通路，促进肿瘤细胞侵袭转移。
3. **文献名称**：**"Structural analysis of CKLFSF5 reveals a potential role in immune modulation"**
**作者**：Chen R, et al.
**摘要**：利用X射线晶体学解析重组CKLFSF5蛋白的三维结构，揭示其特有的跨膜结构域可能参与T细胞活化的负向调控，为免疫治疗提供新靶点。
4. **文献名称**：**"Recombinant CKLFSF5 suppresses angiogenesis in a murine tumor model"**
**作者**：Li X, et al.
**摘要**：研究显示重组CKLFSF5蛋白通过抑制VEGF信号通路，显著降低荷瘤小鼠的微血管密度，提示其抗肿瘤血管生成潜力。
**注**：以上为模拟文献，实际研究建议通过PubMed或SciHub以关键词“CKLFSF5 recombinant”、“CKLFSF5 function”检索近期文献。
Recombinant human CKLFSF5 (Chemokine-like factor superfamily member 5) is a protein encoded by the *CKLFSF5* gene, also known as *CMTM5*. It belongs to the chemokine-like factor (CKLF) superfamily, which shares structural homology with chemokines but exhibits diverse roles in immune regulation, cellular proliferation, and apoptosis. CKLFSF5 is a transmembrane protein containing conserved MARVEL and chemokine-like domains, and it may undergo proteolytic processing to generate secreted isoforms.
Functionally, CKLFSF5 is implicated in tumor suppression and immune modulation. Studies suggest it regulates cell migration, adhesion, and survival via interactions with membrane receptors or extracellular matrix components. It is often downregulated in cancers, including prostate, lung, and hepatocellular carcinoma, correlating with tumor progression and poor prognosis. CKLFSF5 may inhibit oncogenic signaling pathways (e.g., EGFR, MAPK) and enhance apoptosis through caspase activation. Its role in immune responses remains less defined, though it potentially influences T-cell activity and cytokine secretion.
Recombinant CKLFSF5 protein, typically produced in *E. coli* or mammalian systems, retains bioactivity for *in vitro* and *in vivo* studies. It serves as a tool to investigate its tumor-suppressive mechanisms and therapeutic potential. Challenges include elucidating its precise ligands, signaling cascades, and tissue-specific functions. Current research focuses on leveraging CKLFSF5’s anti-cancer properties for targeted therapies or biomarker development, though clinical applications remain exploratory.
×
